Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionBnp Paribas Arbitrage, Sa
Latest Disclosed Ownership280,965 shares
Latest Disclosed Value $ 92,962,890
Bnp Paribas Arbitrage, Sa ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - Bnp Paribas Arbitrage, Sa filed a 13F-HR form disclosing ownership of 280,965 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $80,271,700 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 389,435 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -27.85% during the quarter. The current value of the position is $73,191,382 USD.

Bnp Paribas Arbitrage, Sa has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Alnylam Pharmaceuticals Equity 02043Q107 280,965 -108,470 -27.85 92,963 -39.97 0.0046
2026-02-10 2025-12-31 13F Alnylam Pharmaceuticals Equity 02043Q107 389,435 236,396 154.47 154,859 121.91 0.0702
2025-11-13 2025-09-30 13F Alnylam Pharmaceuticals Equity 02043Q107 153,039 24,405 18.97 69,786 66.37 0.0373
2025-08-14 2025-06-30 13F Alnylam Pharmaceuticals Equity 02043Q107 128,634 86,059 202.14 41,946 264.87 0.0240
2025-05-14 2025-03-31 13F Alnylam Pharmaceuticals Equity 02043Q107 42,575 857 2.05 11,496 17.11 0.0068
2025-02-14 2024-12-31 13F Alnylam Pharmaceuticals Equity 02043Q107 41,718 -73,066 -63.66 9,817 -68.91 0.0055
2024-11-13 2024-09-30 13F Alnylam Pharmaceuticals Equity 02043Q107 114,784 -11,228 -8.91 31,569 3.10 0.0212
2024-08-13 2024-06-30 13F Alnylam Pharmaceuticals Equity 02043Q107 126,012 24,566 24.22 30,621 101.97 0.0250
2024-05-01 2024-03-31 13F Alnylam Pharmaceuticals Equity 02043Q107 101,446 18,742 22.66 15,161 -4.23 0.0133
2024-02-14 2023-12-31 13F/A-2 Alnylam Pharmaceuticals Equity 02043Q107 82,704 31,301 60.89 15,830 73.90 0.0180
2024-02-07 2023-12-31 13F/A-1 Alnylam Pharmaceuticals Equity 02043Q107 82,704 31,301 15,830 0.0022
2024-02-07 2023-12-31 13F Alnylam Pharmaceuticals Equity 02043Q107 82,704 31,301 15,830 0.0183
2023-11-14 2023-09-30 13F Alnylam Pharmaceuticals Equity 02043Q107 51,403 12,822 33.23 9,103 24.22 0.0117
2023-08-09 2023-06-30 13F Alnylam Pharmaceuticals Equity 02043Q107 38,581 -32,502 -45.72 7,328 -48.54 0.0092
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 71,083 42,972 152.87 14,239 113.16 0.0200
2023-02-14 2022-12-31 13F Alnylam Pharmaceuticals Equity 02043Q107 28,111 -61,239 -68.54 6,681 -62.65 0.0103
2022-11-16 2022-09-30 13F/A-1 Alnylam Pharmaceuticals Equity 02043Q107 89,350 32,229 56.42 17,884 114.67 0.0286
2022-11-15 2022-09-30 13F Alnylam Pharmaceuticals Equity 02043Q107 89,350 32,229 17,884 0.0043
2022-08-12 2022-06-30 13F Alnylam Pharmaceuticals Equity 02043Q107 57,121 -9,579 -14.36 8,331 -23.51 0.0130
2022-05-18 2022-03-31 13F/A-1 Alnylam Pharmaceuticals Equity 02043Q107 66,700 681 1.03 10,891 -2.72 0.0146
2022-02-09 2021-12-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 66,019 -11,162 -14.46 11,196 -23.17 0.0159
2021-11-16 2021-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 77,181 57,144 285.19 14,573 329.09 0.0207
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 36,861 16,824 5,367 0.0000
2021-08-10 2021-06-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 20,037 -3,958 -16.50 3,397 0.27 0.0045
2021-05-07 2021-03-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 23,995 -14,050 -36.93 3,388 -31.49 0.0050
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 38,045 1,184 3.21 4,945 -7.86 0.0092
2020-10-30 2020-09-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 36,861 -14,099 -27.67 5,367 -28.90 0.0077
2020-08-06 2020-06-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 50,960 -4,209 -7.63 7,548 25.68 0.0133
2020-05-13 2020-03-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 55,169 -27,553 -33.31 6,005 -36.97 0.0123
2020-02-12 2019-12-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 82,722 36,448 78.77 9,527 156.03 0.0174
2019-11-07 2019-09-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 46,274 -1,681 -3.51 3,721 6.96 0.0066
2019-07-30 2019-06-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 47,955 9,884 25.96 3,480 -2.19 0.0069
2019-04-25 2019-03-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 38,071 -3,898 -9.29 3,558 16.28 0.0077
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 41,969 14,163 50.94 3,060 25.73 0.0072
2018-11-07 2018-09-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 27,806 9,562 52.41 2,434 35.47 0.0036
2018-07-25 2018-06-30 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 18,244 2,870 18.67 1,797 -1.91 0.0030
2018-05-11 2018-03-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 15,374 3,298 27.31 1,831 19.36 0.0034
2018-03-05 2017-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 12,076 2,579 27.16 1,534 37.58 0.0027
2018-02-01 2017-12-31 13F ALNYLAM PHARMACEUTICALS EQUITY 02043Q107 12,076 2,579 1,534
2017-11-03 2017-09-30 13F ALNYLAM PHARMACEUTICALS STOCK 02043Q107 9,497 -3,503 -26.95 1,116 7.63 0.0027
2017-08-03 2017-06-30 13F ALNYLAM PHARMACEUTICALS STOCK 02043Q107 13,000 -2,043 -13.58 1,037 34.55 0.0031
2017-05-03 2017-03-31 13F ALNYLAM PHARMACEUTICALS STOCK 02043Q107 15,043 -728 -4.62 771 30.51 0.0020
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS STOCK 02043Q107 15,771 5,231 49.63 590 -17.37 0.0028
2016-10-05 2016-09-30 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 10,540 -586 -5.27 714 15.72 0.0029
2016-07-06 2016-06-30 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 11,126 2,156 24.04 617 9.59 0.0028
2016-04-22 2016-03-31 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 8,970 1,155 14.78 563 -23.40 0.0024
2016-04-19 2015-12-31 13F/A-1 * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 7,815 -2,968 -27.52 736 -15.13 0.0036
2016-02-10 2015-12-31 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 7,815 736
2015-11-13 2015-09-30 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 10,783 -78,631 -87.94 867 -91.92 0.0022
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 89,414 85,127 1,985.70 10,718 2,297.76 0.0299
2015-05-15 2015-03-31 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 4,287 2,223 107.70 448 123.50 0.0012
2015-03-10 2014-12-31 13F/A-1 * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 2,064 64 3.20 200 28.21 0.0007
2015-02-11 2014-12-31 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 2,064 200
2014-11-12 2014-09-30 13F * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 2,000 -134 -6.28 156 16.42 0.0001
2014-08-14 2014-06-30 13F/A-1 * ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 2,134 1,134 113.40 135 173.47 0.0001
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS INC COM STOCK 02043Q107 2,134 135
2014-05-13 2014-03-31 13F ALNYLAM PHARMACEUTICALS STOCK 02043Q107 1,000 246 32.63 50 2.08 0.0000
2014-04-02 2013-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS STOCK 02043Q107 754 -15,205 -95.28 48 -95.30 0.0000
2013-11-13 2013-09-30 13F ALNYLAM PHARMACEUTICALS STOCK 02043Q107 15,959 -4,443 -21.78 1,022 61.55 0.0007
2013-08-13 2013-06-30 13F ALNYLAM PHARMACEUTICALS STOCK 02043Q107 20,402 20,402 633 0.0004
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-05-01 2024-03-31 13F Alnylam Pharmaceuticals Option Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-07 2023-12-31 13F/A Alnylam Pharmaceuticals Option Put 50 957 n/a n/a n/a
2024-02-14 2023-12-31 13F/A Alnylam Pharmaceuticals Option Put 50 0.00 957 8.14 n/a n/a n/a
2024-02-07 2023-12-31 13F Alnylam Pharmaceuticals Option Put 50 957 n/a n/a n/a
2023-11-14 2023-09-30 13F Alnylam Pharmaceuticals Option Put 50 -83.92 886 -85.02 n/a n/a n/a
2023-08-09 2023-06-30 13F Alnylam Pharmaceuticals Option Put 311 -11.40 5,907 -15.99 n/a n/a n/a
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS OPTION Put 351 7,031 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.